Psychedelics company ATAI raises $125 million Series C funding round - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 51%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

A major psychedelics company just landed a record sum of cash from VCs. The CEO told us how he raised the mega-round and why it's a sign psychedelics are going mainstream.

In this Friday, May 24, 2019 photo a vendor bags psilocybin mushrooms at a pop-up cannabis market in Los Angeles.ATAI Life Sciences closed a $125 million Series C round, marking the biggest funding round to date in the psychedelics space.

ATAI invests in and acquires companies looking to develop medicines for mental-health conditions from psychedelics like psilocybin, arketamine, and ibogaine. The round announced Monday came from investors including Thiel, Galaxy, Falcon Edge Capital, Catalio Capital Management, and ATAI founder Christian Angermayer's family office Apeiron Investment Group.The CEO of a $1.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

wow

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 729. in İD

Indonesia Berita Terbaru, Indonesia Berita utama